Celgene Slips; Drug Candidate Fails Phase III Trial Endpoint By: Benzinga via Benzinga July 09, 2014 at 09:37 AM EDT Celgene's (NASDAQ: CELG) shares slipped nearly two percent in pre-market trading after the company said its drug candidate for ... Read More >> Related Stocks: Celgene Corp